PENのチャート
PENの企業情報
| symbol | PEN |
|---|---|
| 会社名 | Penumbra Inc （PENUMBRA INC） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | ペナムブラ(Penumbra Inc.)は介入療法に従事するヘルスケア会社である。同社は医療機器の設計・開発・製造・販売を行う。同社は神経および末梢血管の2つの市場における医療状況および臨床ニーズに対応する製品ポートフォリオを有する。その製品が扱う条件には、虚血性脳卒中、出血性脳卒中、および血栓摘出および塞栓形成処置によって治療することができる多様な末梢血管状態が含まれる。同社は介入ニューロラジオロジスト、神経外科医、介入神経学者、介入放射線医および血管外科医を含む、専門医による使用のための製品の開発・製造・販売を行う。その神経製品には、神経血管アクセス、神経血栓摘出（虚血性脳卒中）、神経血管塞栓（脳動脈瘤）および神経外科ツール（出血性脳卒中）が含まれる。その末梢血管製品には、末梢血管塞栓術および末梢血栓摘除術が含まれる。 ペナンブラは米国の医療器具メ―カ―。主に、神経系と周辺血管向け医療器具の開発、製造、商業化に従事する。同社の主要製品は、虚血性脳卒中や出血性脳卒中など周辺血管における疾患に対し、梗塞を防ぐために速やかに行う血栓摘出術や血管塞栓術の際に使用される。同社独自ル―トや卸売業者を通じ、米国内外の病院に販売される。本社はカリフォルニア州。 Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra, the Penumbra P logo, Indigo, CAT, Separator, Lightning, and Penumbra ENGINE are trademarks of Penumbra, Inc. |
| 本社所在地 | One Penumbra Place Alameda CA 94502 USA |
| 代表者氏名 | Adam Elsesser |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer |
| 電話番号 | +1 510-995-2486 |
| 設立年月日 | 2004年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 2200人 |
| url | www.penumbrainc.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） 36.15100 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 4884.71100 |
| 売上高 | （百万ドル） 444.93800 |
| 企業価値(EV) | （百万ドル） 4683.82200 |
| 当期純利益 | （百万ドル） 6.58800 |
| 決算概要 | BRIEF: For the fiscal year ended 31 December 2018 Penumbra Inc revenues increased 33% to $444.9M. Net income before extraordinary items decreased 70% to $6.7M. Revenues reflect United States segment increase of 33% to $290.7M Other International segment increase of 39% to $112.4M. Net income was offset by Sales General and Administrative -Other increase of 25% to $209.2M (expense) Research and Development - Other increase of 14% to $34.6M (expense). |
PENのテクニカル分析
PENのニュース
Penumbra: Deep Dive Answering Key Investment Questions (NYSE:PEN) 2023/04/07 10:35:01 Seeking Alpha
Penumbra has demonstrated its capacity to unlock long-term shareholder value. Click here to find out why PEN stock is a Buy.
Penumbra, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 2, 2023 2023/04/04 20:05:00 PR Newswire
ALAMEDA, Calif., April 4, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2023 after market close on Tuesday, May 2, 2023 at 4:30 PM Eastern Time. A press release with first quarter 2023…
Penumbra Earnings Perspective: Return On Capital Employed 2023/02/27 14:47:24 Benzinga
According to Benzinga Pro, during Q4, Penumbra (NYSE: PEN ) earned $3.88 million, a 270.72% increase from the preceding quarter. Penumbra also posted a total of $221.22 million in sales, a 3.53% increase since Q3. In Q3, Penumbra brought in $213.68 million in sales but lost $2.27 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative … Full story available on Benzinga.com
Penumbra, Inc. - Consensus Indicates Potential -2.1% Downside - DirectorsTalk Interviews 2023/02/24 12:05:30 DirectorsTalk
Penumbra, Inc. - Consensus Indicates Potential -2.1% Downside
Penumbra, Inc. Files Mixed Shelf 2023/02/24 10:51:01 Investing.com
https://www.investing.com/news/assorted/penumbra-inc-files-mixed-shelf-432SI-3013489
Penumbra Inc Shares Near 52-Week High - Market Mover 2023/02/08 00:00:00 Kwhen Finance
Penumbra Inc (PEN) shares closed today at 0.4% below its 52 week high of $268.49, giving the company a market cap of $10B. The stock is currently up 20.1% year-to-date, up 20.3% over the past 12 months, and up 182.0% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 28.4% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 311.6% The company's stock price performance over the past 12 months beats the peer average by -212.5%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Penumbra PT Raised to $297 at Deutsche Bank 2023/02/07 14:11:12 Investing.com
https://www.investing.com/news/pro/penumbra-pt-raised-to-297-at-deutsche-bank-432SI-2997179
Penumbra Inc Shares Climb 0.2% Past Previous 52-Week High - Market Mover 2023/02/07 00:00:00 Kwhen Finance
Penumbra Inc (PEN) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $9B. The stock is currently up 16.7% year-to-date, up 18.1% over the past 12 months, and up 175.8% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 57.9% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 294.7% The company's stock price performance over the past 12 months beats the peer average by -196.8%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Google has the next move as Microsoft embraces OpenAI buzz 2023/02/01 16:35:50 Financial Post
NEW YORK (AP) — Before the artificial intelligence tool ChatGPT was unleashed into the world, the novelist Robin Sloan was testing a similar AI writing assistant built by researchers at Google. It didn’t take long for Sloan, author of the bestseller “Mr. Penumbra’s 24-hour Bookstore,” to realize that the technology was of little use to […]
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 23, 2023 2023/01/26 21:05:00 PR Newswire
ALAMEDA, Calif., Jan. 26, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023 at 4:30 PM Eastern Time. A press release…
Google has the next move as Microsoft embraces OpenAI buzz 2023/02/01 16:35:50 Financial Post
NEW YORK (AP) — Before the artificial intelligence tool ChatGPT was unleashed into the world, the novelist Robin Sloan was testing a similar AI writing assistant built by researchers at Google. It didn’t take long for Sloan, author of the bestseller “Mr. Penumbra’s 24-hour Bookstore,” to realize that the technology was of little use to […]
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 23, 2023 2023/01/26 21:05:00 PR Newswire
ALAMEDA, Calif., Jan. 26, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023 at 4:30 PM Eastern Time. A press release…
Penumbra – Consensus Indicates Potential 2.7% Upside 2023/01/20 11:22:39 DirectorsTalk
Penumbra found using ticker (PEN) now have 10 analysts covering the stock. The analyst consensus points to a rating of ''Strong_Buy''. The range between the high target price and low target price is between 270 and 195 calculating the mean target price we have 246. With the stocks previous close at 239.51 this now indicates there is a potential upside of 2.7%. The day 50 moving average is 211.43 and the 200 day moving average is 174.74. The market capitalisation for the company is $9,102m. You can visit the company''s website by visiting: https://www.penumbrainc.com [stock_market_widget type="chart" template="basic" color="green" assets="PEN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $9,349m based on the market concensus. Penumbra designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands.
US Neurovascular Devices/ Interventional Neurology Market 2023-2030: Updated Statistics, Technology landscape and Growth Opportunities | Stryker Corporation, Johnson & Johnson, Medtronic, Terumo, Penumbra 2023/01/20 05:03:46 Express Press Release Distribution
NEW YORK, 2023-Jan-20 — /EPR Network/ — “Neurovascular Devices/ Interventional Neurology Market Report, 2022 to 2030 Neurovascular Devices/ Interventional Neurology Market study performed by market [read full press release…]